Iemand bekend met het aandeel PSID?
WINDSOR, ON / ACCESSWIRE / February 3, 2016 / The Wealthy Biotech Trader (or "WBT"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, has researched several stocks on the front lines in the fight against Zika, an epidemic spreading from South America that causes flu-like symptoms but is feared to cause horrible birth defects in babies whose mothers become infected.COMPANIES MENTIONED: PositiveID Corporation(PSID); Inovio Pharmaceuticals, Inc. (INO);Chimerix, Inc. (CMRX); BioCryst Pharmaceuticals, Inc. (BCRX); Intrexon Corporation (NYSE:XON).Over the past 12 months PositiveID (PSID) has transformed into quite the horizontally integrated powerhouse with complementary businesses ranging from real time pathogen/ biological threat detection testing units (Firefly Dx), to non-contact thermometers (Thermomedics: acquired by PSID December 8th, 2015), to mobile communication and lab vehicles for homeland security and biological testing in the field (E-N-G Mobile Systems: Acquired by PSID December 29th, 2016).Why PSID is important with regards to protecting the rest of the world from the Zika virus is that just last week their assay testing partner, GenArraytion, announced they have introduced the first commercially available test to identify the Zika virus. It's important to note that PSID has been, and continues to, successfully test for and detect pathogens using many of GenArraytion's assays on the Firefly Dx breadboard prototype system in under 30 minutes.The real moon shot for PSID would be the completion of R&D and subsequent commercialization of their Firefly Dx unit (Q4 '16 – Q1 '17), which is eccentrically a "lab in hand" device for the real-time PCR industry, estimated to be a $5.6 billion market by 2020. The tiny unit would be able to test anyone or anything for threats from Ebola to Zika to MRSA to C. diff in less than 30 minutes (a lab can take hours to days from sample to result), with lab quality results at a fraction of the cost.PSID just announced revenue growth of 200% for the first 9 months of 2015 in comparison with the same period in 2014, and PSID appears to be in great shape to grow their two acquired businesses to add similar growth for 2016. This excludes Firefly Dx and the potential with Zika.